Last reviewed · How we verify
TOFA
At a glance
| Generic name | TOFA |
|---|---|
| Sponsor | Pfizer |
| Target | Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Juvenile idiopathic arthritis, extended oligoarthritis
- Juvenile psoriatic arthritis
- Polyarticular juvenile idiopathic arthritis
- Psoriatic arthritis
- Rheumatoid arthritis
- Ulcerative colitis
Common side effects
- Overall Infections
- Upper Respiratory Tract Infections
- Nasopharyngitis
- Urinary Tract Infections
Serious adverse events
- Serious Infections
Key clinical trials
- Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA) (PHASE4)
- Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients (PHASE4)
- The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis (PHASE2)
- Opioid Free Anesthesia on the Quality of Early Recovery (NA)
- Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy
- Examination of Efficacy and Safety of Baricitinib in RA Patients (PHASE2)
- Tofacitinib for Inflammatory Eye Disease (PHASE2)
- A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494 (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TOFA CI brief — competitive landscape report
- TOFA updates RSS · CI watch RSS